Top Page
Genmab
(NASDAQ:GMAB)
Genmab (GMAB) vs. SPDR S&P 500 ETF (SPY)
Genmab Business Overview & Revenue Model
Genmab Earnings Call Summary
Genmab Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.04B | 21.53B | 16.47B | 14.51B | 8.42B | 10.11B |
| Gross Profit | 13.24B | 20.54B | 16.25B | 14.51B | 8.42B | 10.11B |
| EBITDA | 5.96B | 9.70B | 5.95B | 7.35B | 4.18B | 6.16B |
| Net Income | 6.57B | 7.84B | 4.35B | 5.45B | 2.96B | 4.76B |
Balance Sheet | ||||||
| Total Assets | 7.02B | 45.81B | 35.29B | 30.12B | 24.63B | 21.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.41B | 21.10B | 28.14B | 22.32B | 19.34B | 16.08B |
| Total Debt | 142.00M | 1.03B | 770.00M | 597.00M | 425.00M | 319.00M |
| Total Liabilities | 1.27B | 9.11B | 3.68B | 2.84B | 2.43B | 2.02B |
| Stockholders Equity | 5.75B | 36.70B | 31.61B | 27.28B | 22.20B | 19.12B |
Cash Flow | ||||||
| Free Cash Flow | 2.91B | 7.58B | 7.00B | 3.60B | 1.98B | 6.13B |
| Operating Cash Flow | 3.21B | 7.77B | 7.38B | 3.91B | 2.23B | 6.43B |
| Investing Cash Flow | -67.42M | -9.91B | -1.28B | -2.76B | -961.00M | -2.35B |
| Financing Cash Flow | -2.64B | -3.92B | -606.00M | -789.00M | -420.00M | 71.00M |
Genmab Technical Analysis
Genmab Risk Analysis
Genmab Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $20.14B | 17.21 | 30.39% | ― | 18.09% | 3563.21% | |
80 Outperform | $25.22B | 24.57 | 11.51% | 2.23% | 3.72% | -31.46% | |
76 Outperform | $19.53B | 13.44 | 28.20% | ― | 24.98% | 127.06% | |
71 Outperform | $11.07B | 21.59 | 9.07% | ― | 12.31% | 60.21% | |
53 Neutral | $26.15B | -41.37 | -2.94% | ― | 7.04% | -25.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $13.43B | -51.74 | ― | ― | 103.32% | 47.55% |
Genmab Corporate Events
On January 21, 2026, Genmab reported that 2025 worldwide net trade sales of the multiple myeloma therapy DARZALEX (daratumumab), including its subcutaneous formulation DARZALEX FASPRO, reached USD 14.351 billion, according to figures from license partner Johnson & Johnson’s Janssen unit. Sales totaled USD 8.266 billion in the United States and USD 6.085 billion in the rest of the world, and Genmab earns royalties on all global DARZALEX sales under its exclusive worldwide license agreement with J&J, underscoring the product’s continued commercial strength and its importance as a major revenue driver for the Danish biotech.
The most recent analyst rating on (GMAB) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On January 16, 2026, Genmab reported topline Phase 3 results from its global EPCORE DLBCL-1 trial of subcutaneous bispecific antibody epcoritamab in patients with relapsed or refractory diffuse large B‑cell lymphoma who were ineligible for high‑dose chemotherapy and autologous stem cell transplant. The study, which enrolled 483 patients and compared epcoritamab monotherapy with standard chemo‑immunotherapy regimens R‑GemOx or BR, showed a statistically significant improvement in progression‑free survival and gains in complete response rate, duration of response and time to next treatment, while overall survival did not reach statistical significance and safety findings appeared consistent with the known profile. Genmab and partner AbbVie plan to discuss the data with global regulators and continue to position epcoritamab as a potential core therapy across B‑cell malignancies, supported by multiple ongoing Phase 3 programs in both frontline and relapsed DLBCL and follicular lymphoma that could further expand its clinical and commercial footprint if successful.
The most recent analyst rating on (GMAB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On December 29, 2025, Genmab announced it would discontinue further clinical development of acasunlimab following a portfolio review and assessment of a more competitive market landscape. Although the company described the drug’s clinical profile to date as encouraging, management said it will redirect resources toward late-stage programs it sees as having higher potential impact, notably EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina-S). The move underscores Genmab’s disciplined approach to portfolio prioritization and capital allocation, and the company emphasized that the decision will not affect its full-year 2025 financial guidance, reassuring investors that its broader pipeline momentum and financial outlook remain intact.
The most recent analyst rating on (GMAB) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On December 12, 2025, Genmab A/S announced the successful completion of its tender offer to acquire all outstanding common shares of Merus N.V. for $97 per share, marking a significant step in its strategy to become a global biotechnology leader. This acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio, and is expected to be accretive to the company’s EBITDA by the end of 2029, with potential multi-billion-dollar annual revenue thereafter.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On December 1, 2025, Genmab A/S announced transactions involving shares and linked securities conducted by its managerial employees and their closely associated persons. These transactions, which were acquisitions due to the vesting of restricted stock units, reflect internal movements within the company’s stock holdings. The disclosure is in compliance with market regulations and highlights the vested interests of key personnel in Genmab’s operational success.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On November 26, 2025, Genmab A/S announced updates to its Articles of Association, which include authorizations for the Board of Directors to increase the company’s share capital and issue warrants and convertible debt instruments. These changes are aimed at providing financial flexibility and supporting the company’s growth strategy, potentially impacting shareholder value and market positioning.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On November 20, 2025, Genmab A/S announced the grant of 6,933 restricted stock units and 7,377 warrants to its employees and subsidiaries. These grants are part of Genmab’s compensation strategy to incentivize and retain talent, with the restricted stock units and warrants vesting over a period of three years. This move underscores Genmab’s commitment to aligning employee interests with company growth and enhancing its competitive positioning in the biotechnology industry.
The most recent analyst rating on (GMAB) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On November 19, 2025, Genmab A/S announced transactions involving shares and linked securities conducted by its managerial employees and their closely associated persons. These transactions, disclosed in accordance with market abuse regulations, involved the sale of 175 shares at an average price of DKK 1,960.35 across multiple exchanges. This announcement reflects the company’s transparency in financial dealings, potentially impacting stakeholder trust and market perception.
The most recent analyst rating on (GMAB) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Genmab A/S has updated its Articles of Association, authorizing the Board of Directors to increase the company’s share capital and issue warrants and convertible debt instruments. These changes, effective until 2029, aim to provide flexibility in capital management and potentially enhance shareholder value.
The most recent analyst rating on (GMAB) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On November 18, 2025, Genmab A/S announced a capital increase of 32,059 shares following the exercise of employee warrants, generating approximately DKK 43.2 million. This increase, which represents about 0.05% of the company’s share capital, will be listed on Nasdaq Copenhagen and is expected to be finalized shortly. The new shares are ordinary, freely transferable, and come with rights to dividends. This move reflects Genmab’s ongoing efforts to enhance its financial position and support its strategic goals in the biotechnology sector.
The most recent analyst rating on (GMAB) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On November 18, 2025, Genmab A/S announced that the U.S. FDA approved EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma. This approval is significant as it marks the first FDA approval for a bispecific combination therapy in the lymphoma space, potentially setting a new standard of care. The approval was based on the Phase 3 EPCORE® FL-1 trial, which demonstrated superior progression-free survival and overall response rates compared to standard treatments. The approval could enhance Genmab’s positioning in the oncology market and provide new treatment options for patients with follicular lymphoma.
The most recent analyst rating on (GMAB) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On November 10, 2025, Genmab A/S announced a proposed private offering of $1.5 billion in senior secured notes due 2032 and $1.0 billion in senior unsecured notes due 2033, alongside the syndication of a new $2.0 billion senior secured term loan facility. The funds raised will be used to finance the acquisition of Merus N.V., a strategic move expected to enhance Genmab’s market position in the biotechnology sector. The offering is part of a broader financing strategy that includes previously syndicated credit facilities, and it underscores Genmab’s commitment to expanding its operational capabilities and market reach.
The most recent analyst rating on (GMAB) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On November 6, 2025, Genmab announced its financial results for the first nine months of 2025, reporting a 21% increase in revenue to $2,662 million, driven by higher royalties from DARZALEX and Kesimpta. The company also revealed its proposed acquisition of Merus N.V., a move expected to enhance its late-stage portfolio and accelerate its growth as a global biotechnology leader. This acquisition, valued at approximately $8 billion, is anticipated to close by early 2026, subject to customary conditions.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.